ViCentra bolsters leadership team with the appointment of Leo Toole as Chief Financial Officer and expands European commercialization
- Newly appointed CFO with significant experience in medical technology and public / private financing
- Insulin Pump system Kaleido to expand commercial roll out in Europe
February 1, Utrecht, The Netherlands
ViCentra B.V., the company behind Kaleido, one of the world’s smallest, lightest and most precise Insulin Pump systems for treating people with type 1 Diabetes, is pleased to announce the appointment of Leo Toole as Chief Financial Officer and provides a corporate update on its expansion pathway of Kaleido into key European markets in 2023.